Treatment of bone disorders with skeletal anabolic drugs

Details Treatment of bone disorders with skeletal anabolic drugs Treatment of bone disorders with skeletal anabolic drugs

2008-06-10

2008-06-10

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C530S324000

Reexamination Certificate

active

07384912

ABSTRACT:
Disclosed herein are methods for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass, including osteoporosis. The present invention provides methods of using PTHrP, or analogs thereof, for the treatment of metabolic bone disorders that are both effective and have an increased safety.

REFERENCES:
patent: 4656250 (1987-04-01), Morita et al.
patent: 4771124 (1988-09-01), Rosenblatt et al.
patent: 5229489 (1993-07-01), Kanmera et al.
patent: 5589452 (1996-12-01), Krstenansky et al.
patent: 5595760 (1997-01-01), Cherif-Cheikh
patent: 5605815 (1997-02-01), Broadus et al.
patent: 5688760 (1997-11-01), Kemp et al.
patent: 5693616 (1997-12-01), Krstenansky et al.
patent: 5695955 (1997-12-01), Krstenansky et al.
patent: 5700774 (1997-12-01), Hattersley et al.
patent: 5703207 (1997-12-01), Martin et al.
patent: 5747456 (1998-05-01), Chorev et al.
patent: 5798225 (1998-08-01), Krstenansky et al.
patent: 5807823 (1998-09-01), Krstenansky et al.
patent: 5821225 (1998-10-01), Vickery
patent: 5821823 (1998-10-01), Bereza
patent: 5840837 (1998-11-01), Krstenansky et al.
patent: 5847086 (1998-12-01), Farb et al.
patent: 5849695 (1998-12-01), Cohen et al.
patent: 5874086 (1999-02-01), Krstenansky et al.
patent: 5977070 (1999-11-01), Piazza et al.
patent: 6051686 (2000-04-01), Krstenansky et al.
patent: 6147186 (2000-11-01), Gardella et al.
patent: 6273598 (2001-08-01), Keck et al.
patent: 6362163 (2002-03-01), Gardella et al.
patent: 6495662 (2002-12-01), Gardella et al.
patent: 6544949 (2003-04-01), Dong
patent: 6583114 (2003-06-01), Vickery
patent: 6756480 (2004-06-01), Kostenuik et al.
patent: 6787518 (2004-09-01), Kato et al.
patent: 6849710 (2005-02-01), Arzeno
patent: 6921750 (2005-07-01), Dong
patent: 6977077 (2005-12-01), Hock et al.
patent: 7015195 (2006-03-01), Stewart
patent: 7057012 (2006-06-01), Gardella et al.
patent: 2002/0077281 (2002-06-01), Vickery
patent: 4203040 (1993-08-01), None
patent: 293158 (1988-11-01), None
patent: 451867 (1991-10-01), None
patent: 477885 (1992-04-01), None
patent: 561412 (1993-09-01), None
patent: 1 059 933 (2003-01-01), None
patent: 0 822 200 (2004-09-01), None
patent: 1 595 532 (2005-11-01), None
patent: WO 92/00753 (1992-01-01), None
patent: WO 92/10515 (1992-06-01), None
patent: WO 92/11286 (1992-07-01), None
patent: WO 93/06846 (1993-04-01), None
patent: WO 93/20203 (1993-10-01), None
patent: WO 94/01460 (1994-01-01), None
patent: WO 94/02510 (1994-02-01), None
patent: WO 94/03201 (1994-02-01), None
patent: WO 95/02610 (1995-01-01), None
patent: WO-98/04591 (1998-02-01), None
patent: WO 98/05683 (1998-02-01), None
patent: WO 99/12561 (1999-03-01), None
patent: WO-99/55310 (1999-11-01), None
patent: WO-00/10596 (2000-03-01), None
patent: WO-00/18954 (2000-04-01), None
patent: WO-01/22093 (2001-03-01), None
patent: WO-01/85784 (2001-11-01), None
patent: WO-01/98348 (2001-12-01), None
patent: WO-02/28420 (2002-04-01), None
patent: WO-02/068585 (2002-09-01), None
patent: WO-03/026689 (2003-04-01), None
patent: WO-03/039534 (2003-05-01), None
patent: WO-2004/060386 (2004-07-01), None
Abou-Samra et al.,Endocrinology, 125: 2594-2599 (1989).
Abou-Samra et al.,Endocrinology, 129: 2547-2554 (1991).
Blind et al.,Clin. Endocrinol., 101: 150-155 (1993).
Brown et al.,Biochem., 20:4538-4546 (1981).
Burtis et al.,J. Biol. Chem., 262: 7151-7156 (1987).
BurtisClin. Chem., 38: 2171-2183 (1992).
Carter et al.,Biochim. Biophys. Acta, 538: 290-304 (2001).
Casey et al.,Nucl. Acid Res., 4: 1539 (1977).
Caufield et al.,Endocrinol., 123:2949-2951 (1988).
Caye et al.,J. Clin. Endocrinol., Metab., 81: 199-208 (1996).
Chestnut et al.,Osteoporosis Int 8(sup pl 3): 13 (1998).
Chorev et al.,J. Bone. Min. Res., 4: S270 (1989).
Cohen et al.,J. Biol. Chem., 266:1997-2004 (1991).
Dayhoff et al., 5 Atlas of Protein Sequence and Structure, 345-352. (1978 & Suppl.).
Delmas et al.,N. Engl. J. Med., 337: 1641-1647 (1997).
Dempster et al.,Endocrine Reviews, 14:690-709 (1993).
Dobnig & Turner,Endocrinology, 138:4607-4612 (1997).
Ettinger et al.,JAMA, 282:637-45 (1999).
Finkelstein et al.,N. Engl J. Med., 331: 1618-1623 (1994).
Fitzpatrick et al.,J. Biol. Chem., 244: 3561-3569 (1969).
Fogelman et al., J. Clin. Endocrinol. Metab., 85:1895-1900 (2000).
Frolick et al.,J. Bone Min. Res., 14: 163-72 (1999).
Fujimori et al.,Endocrinology, 130: 29-60 (1992).
Fujimori et al.,Endocrinology, 128: 3032-3039 (1991).
Fukuyama et al.,Endocrinology, 131: 1757-1769 (1992).
Fukayama et al.,Endocrinology, 134: 1851-1858 (1994).
Gamse et al.,J. Bone Min. Res.; 12(suppl): S317 (1997).
Gundberg, et al., J. Clin. Endocrinol. Metab., 83:3258-3266, (1998).
Henry et al.,J. Clin. Endocrinol. Metab., 82: 900-906 (1997).
Hirano et al.,J. Bone. Min. Res., 14: 536-545 (1999).
Hock et al.,Endocrinology, 125: 2022-2027 (1989).
Hock et al.,J. Bone. Min. Res., 7: 65-72 (1992).
Hodsman et al.,J. Clin. Endocrinol. Metab., 82: 620-628 (1997).
Janulis et al.,Endocrinology, 133: 713-719 (1993).
Jouishomme et al.,Endocrinology, 130: 53-60 (1992).
Juppner et al.,J. Biol., Chem., 263: 8557-8560 (1988).
Karaplis A.C.,. Abstract 1052, Annual Meeting of the American Society for Bone and Mineral Research, Sep. 2002, San Antonio, TX.J. Bone Mineral Res., 17(Suppl. 1), S138 (2002).
Lane et al.,J Clin. Invest., 102: 1627-1633 (1998).
Liberman et al.,N. Engl. J. Med., 333: 1437-1443 (1995).
Lindsay et al.,Lancet, 350: 550-555 (1997).
McClung et al.,N. Engl. J. Med., 344: 333-40 (2001).
Merendino et al.,Science, 231: 388-390 (1986).
Moseley et al.,Proc. Natl. Acad. Sci. USA., 84 5048-5052 (1987).
Munson et al.,Anal. Biochem., 107:220-239 (1980).
Murphy et al., J. Clin. Endocrinol. Metab., 86:1116-25 (2001).
Neer et al.,N. Engl. J. Med., 344: 1434-1441 (2001).
Orloff et al.,J. Biol. Chem., 264: 6097-6103 (1989).
Orloff et al.,J. Bone Min. Res., 6: 279-287 (1991).
Orloff et al.,Endocrinology, 131: 1603-1611 (1992).
Orloff et al.Am. J. Phsiol., 262: E599-E607 (1992).
PEPI Trial,JAMA, 276: 1389-1396 (1996).
Pines et al.,Endocrinology, 135: 1713-1716 (1994).
Plotkin et al.,J. Clin. Endocrinol. Metab., 83: 2786-2791 (1998).
Reid et al.,N. Engl. J. Med., 346:653-61 (2002).
Roe et al.,Program and Abstracts of the 81st Annual Meeting of the Endocrine Society, San Diego, CA, Jun. 12-15, p. 59 (1999).
Rosen et al.,J. Clin. Endocrinol. Metab., 86: 957-964 (2001).
Schermer,J. Bone&Min. Res., 6: 149-155 (1991).
Shimizu et al.,J. Biol. Chem., 276: 49003-49012 (2001).
Shimizu et al.,Endocrinology, 42: 3068-3074 (2001).
Shimizu et al.,J. Biol. Chem., 275: 21836-21843 (2000).
Sistare et al.,Pharmacopeial Forum, 20: 7509-7520 (1994).
Stewart et al.,N. Engl. J. Med., 303: 1377-1383 (1980).
Stewart et al.,J. Clin. Endo. Metab., 55: 219-227 (1982).
Stewart et al.,Biochem. Biophys. Res. Comm., 146: 672-678 (1987).
Stewart et al.,J. Clin. Invest., 81: 596-600 (1988).
Stewart et al.,J. Bone Min. Res., 15: 1517-1525 (2000).
Strewler et al.,J. Clin. Invest., 80: 1803 (1987).
Vickery et al.,J. Bone Miner. Res., 11: 1943-1951 (1996).
Wu et al.,J. Biol. Chem., 271: 24371-24381 (1996).
Yang et al.,Biochem., 33: 7460-7469 (1994).
Yasuda et al.,J. Biol. Chem., 264: 7720-7725 (1989).
Stewart, A.F., “PTHrP(1-36) as a Skeletal Anabolic Agent for the Treatment of Osteoporosis;” BONE, vol. 19, No. 4; Oct. 1996; pp. 303-306.

Affiliated with

Also associated with

Rating

Treatment of bone disorders with skeletal anabolic drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of bone disorders with skeletal anabolic drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of bone disorders with skeletal anabolic drugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2811849